Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
28.57
+0.24 (0.85%)
At close: Mar 9, 2026, 4:00 PM EDT
28.62
+0.05 (0.18%)
After-hours: Mar 9, 2026, 4:13 PM EDT
HRMY Employees
Harmony Biosciences Holdings had 293 employees as of December 31, 2025. The number of employees increased by 25 or 9.33% compared to the previous year.
Employees
293
Change (1Y)
25
Growth (1Y)
9.33%
Revenue / Employee
$2,964,003
Profits / Employee
$541,594
Market Cap
1.65B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Innoviva | 159 |
| Pharvaris | 118 |
| AnaptysBio | 104 |
| Nanobiotix | 103 |
HRMY News
- 5 days ago - Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
- 13 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion - Business Wire
- 20 days ago - Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy - Business Wire
- 27 days ago - Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 7 weeks ago - Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
- 2 months ago - Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire